Author(s): Jankovic J, Beach J
Abstract Share this page
Abstract Over the past 15 years we have treated 526 patients with severe hyperkinetic movement disorders with tetrabenazine (TBZ), a monoamine-depleting and a dopamine-receptor-blocking drug. We report here the results in 400 patients with adequate follow-up. The response was rated on a scale of 1 to 5 (1 = marked improvement, 4 = no response, 5 = worsening) and was assessed initially and at the last clinic visit. The average duration of TBZ treatment was 28.9 months (+/- 31.1; range, 0.25 to 180 months). The global response rating of 1 (marked improvement) was recorded in 89.2\% of 93 patients with tardive stereotypy, 83.3\% of 12 with myoclonus, 82.8\% of 29 with Huntington's disease, 80.5\% of 82 with tardive dystonia, 79.3\% of 29 with other movement disorders, 62.9\% of 108 with idiopathic dystonia, and in 57.4\% of 47 with Tourette's syndrome. The most common side effects included drowsiness (36.5\%), parkinsonism (28.5\%), depression (15.0\%), insomnia (11.0\%), nervousness or anxiety (10.3\%), and akathisia (9.5\%). The side effects were controlled with reduction in the dosage. TBZ is an effective and safe drug for the treatment of a variety of hyperkinetic movement disorders. In contrast to typical neuroleptics, TBZ has not been demonstrated to cause tardive dyskinesia.
This article was published in Neurology
and referenced in Chemical Sciences Journal